

concentration of 2 mg/mL to minimize the formation of small aggregates. Pre-existing aggregates were removed by SEC on a Superdex 75 HR10/30 column (GE Healthcare, Piscataway, NJ, USA) equilibrated in 40 mmol/L Tris-HCl buffer (pH 8.0) and pre-treated with 1 mg BSA to reduce non-specific binding of A β (1-40) to the resin. [Gonzales-Velasquez, FJ. et al. *J Neurochem* 10.1111/j.1471-4159.2007.04988.x \(2007\).](#)

Samples of 1 mg of A β (1-40) powder (purchased from AnaSpec, Inc.) were dissolved in 0.2 ml of trifluoroacetic acid and gently stirred at 5 °C for 3 h to completely dissolve associated peptides. [Carrotta, R. et al. *J Biol Chem* 280, 30001 \(2005\).](#)

A β (1-40) was purchased from AnaSpec (San Jose, CA). Lyophilized A β (1-40) was solubilized at a concentration of 2.8mM using prefiltered 8M urea, pH 10. After 10 min, samples were diluted to 140 mM A β into filtered PBSA. [Kim, JR. et al. *Biophys J* 86, 3194 \(2004\).](#)

Published Citations:

[Dillen, L. et al. *Bioanalysis* 3, 45 \(2011\).](#)
[Hoi, C. et al. *Phytother Res* 24, 10 \(2010\).](#)
[Keshet, B. et al. *Biotech Bioengineer* 106, 333 \(2010\).](#)
[Vargas, T. et al. *J Biomed Biotech* 10.1155/2010/805405 \(2010\).](#)
[Davis, T.J. et al. *Mol Pharmacol* 10.1124/mol.109.055301 \(2009\).](#)
[Liu, L. et al. *PEDS* 22, 479 \(2009\).](#)
[Liu, L. et al. *Protein Eng Des Sel* 22, 479 \(2009\).](#)
[Muresan, V. et al. *J Neurosci* 29, 3565 \(2009\).](#)
[Andras, IE. et al. *Mol Pharmacol* 10.1124/mol.107.042028 \(2008\).](#)
[Ho, CC. et al. *Food Chem* 114, 246 \(2008\).](#)
[Minicozzi, V. et al. *J Biol Chem* 10.1074/jbc.M707109200 \(2008\).](#)
[Gonzales-Velasquez, FJ. et al. *J Neurochem* 10.1111/j.1471-4159.2007.04988.x \(2007\).](#)
[Guo, J-P. et al. *Proc Natl Acad Sci* 103, 1953 \(2006\).](#)
[Jacobsen, JS. et al. *Proc Natl Acad Sci* 103, 5161 \(2006\).](#)
[Carrotta, R. et al. *J Biol Chem* 280, 30001 \(2005\).](#)
[Osada, Y. et al. *J Biol Chem* 280, 8596 \(2005\).](#)
[Boros, S. et al. *FEBS Lett* 576, 57 \(2004\).](#)
[Ege, C. et al. *Biophys J* 87, 1732 \(2004\).](#)
[Kim, JR. et al. *Biophys J* 86, 3194 \(2004\).](#)
[Watanabi, N. et al. *FASEB J* 18, 1013 \(2004\).](#)
[Kim, JR. et al. *J Biol Chem* 278, 40730 \(2003\).](#)
[Ji, SR. et al. *J Biol Chem* 277, 6273 \(2002\).](#)
[Nakagami, Y. et al. *Eur J Pharma* 457, 11 \(2002\).](#)
[Kajkowski, EM. et al. *J Biol Chem* 276, 18748 \(2001\).](#)
[Pallitto, MM. et al. *Biophys J* 8, 185 \(2001\).](#)
[Liang, JJN. *FEBS Lett* 484, 98 \(2000\).](#)
[Satoh, K. et al. *Neurosci Lett* 283, 221 \(2000\).](#)
[Stege, GJJ. et al. *BBRC* 262, 152 \(1999\).](#)
[Bradt, BM. et al. *J Exp Med* 188, 431 \(1998\).](#)

For Research Use Only